Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis

Hepatology

Volumn 39, Issue 6, 2004, Pages 1631-1638

  Czaja, Albert J ^a   Carpenter, Herschel A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; HLA DR3 ANTIGEN; HLA DR4 ANTIGEN; PREDNISONE;

ADULT; ARTICLE; AUTOIMMUNE HEPATITIS; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE EXACERBATION; DRUG RESPONSE; FEMALE; HISTOPATHOLOGY; HLA SYSTEM; HUMAN; HUMAN TISSUE; ISHAK SCORING SYSTEM; LABORATORY DIAGNOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELAPSE; SCORING SYSTEM; TREATMENT FAILURE;

DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HEPATITIS, AUTOIMMUNE; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PREDNISONE; RETROSPECTIVE STUDIES;

EID: 2542572604     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20235     Document Type: Article

References (46)

1. Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. HEPATOLOGY 2002;36:479-497.
2. Czaja AJ. Treatment of autoimmune hepatitis. Semin Liver Dis 2002;22:365-377.
3. Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol 2004;40:644-650.
4. Davis GL, Czaja AJ, Ludwig J. Development and prognosis of histologic cirrhosis in corticosteroid-treated HBsAg-negative chronic active hepatitis. Gastroenterology 1984;87:1222-1227.
5. Roberts SK, Therneau T, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 1996;110:848-857.
6. Czaja AJ. Treatment strategies in autoimmune hepatitis. Clin Liver Dis 2002;6:799-824.
7. Czaja AJ. Low dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis. HEPATOLOGY 1990;11:1044-1049.
8. Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 1995;333:958-963.
9. Donaldson PT, Doherty DG, Hayllar KM, McFarlane IG, Johnson PJ, Williams R. Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. HEPATOLOGY 1991;13:701-706.
10. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology 1993;105:1502-1507.
11. Czaja AJ, Strettell MDJ, Thomson LJ, Santrach PJ, Moore SB, Donaldson PT, et al. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. HEPATOLOGY 1997;25:317-323.
12. Czaja AJ, Cookson S, Constantini PK, Clare M, Underhill JA, Donaldson PT. Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis. Gastroenterology 1999;117:645-652.
13. Agarwal K, Czaja AJ, Jones DEJ, Donaldson PT. CTLA-4 gene polymorphism and susceptibility to type 1 autoimmune hepatitis. HEPATOLOGY 2000;31:49-53.
14. Soloway RD, Baggenstoss AH, Schoenfield LJ, Summerskill WHJ. Observer error and sampling variability tested in evaluation of hepatitis and cirrhosis by liver biopsy. Am J Dig Dis 1975;20:1087-1090.
15. Theodossi A, Skene AM, Portmann B, Knill-Jones RP, Patrick RS, Tate RA, et al. Observer variation in assessment of liver biopsies including analysis by kappa statistics. Gastroenterology 1980;79:232-241.
16. Arthur MJP. Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. Gastroenterology 2002;122;1525-1528.
17. French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsies in patients with chronic hepatitis C. HEPATOLOGY 1994;20:15-20.
18. Westin J, Lagging LM, Wejstal R, Norkans G, Dhillon AP. Interobserver study of liver histopathology using the Ishak score in patients with chronic hepatitis C virus infection. Liver 1999;19:183-187.
19. Brunt EM. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. HEPATOLOGY 2000;31;241-246.
20. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, et al. International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31:929-938.
21. Czaja AJ, Cassani F, Cataleta M, Valentini P, Bianchi FB. Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. HEPATOLOGY 1996;24:1068-1073.
22. Czaja AJ, Cassani F, Cataleta M, Valentini P, Bianchi FB. Antinuclear antibodies and patterns of nuclear immunofluorescence in type 1 autoimmune hepatitis. Dig Dis Sci 1997;42:1688-1696.
23. Czaja AJ, Manns MP, Homburger HA. Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis. Gastroenterology 1992;103:1290-1295.
24. Summerskill WHJ, Korman MG, Ammon HV, Baggenstoss AH. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut 1975;16:876-883.
25. Czaja AJ, Menon KVN, Carpenter HA. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. HEPATOLOGY 2002;35:890-897.
26. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-699.
27. Bonis PAL, Friedman SL, Kaplan MM. Is liver fibrosis reversible? N Engl J Med 2001;344:452-454.
28. Schvarcz R, Glaumann H, Weiland O. Survival and histological resolution of fibrosis in patients with autoimmune chronic active hepatitis. J Hepatol 1993;18:15-23.
29. Dufour JF, DeLellis R, Kaplan MM. Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med 1997;127:981-985.
30. Cotler SJ, Jakate S, Jensen DM. Resolution of cirrhosis in autoimmune hepatitis with corticosteroid therapy. J Clin Gastroenterol 2001;32:428-430.
31. Friedman SL. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med 1993;328:1828-1835.
32. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000;275:2247-2250.
33. Almawi WY, Beyhum HN, Rahme AA, Rieder MJ. Regulation of cytokine and cytokine receptor expression by glucocorticoids. J Leukoc Biol 1996;60:563-572.
34. Almawi WY. Molecular mechanisms of glucocorticoid effects. Mod Asp Immunobiol 2001;2:78-82.
35. Iredale JP, Benyon RC, Pickering J, McCullen M, Northrop M, Pawley S, et al. Mechanisms of spontaneous resolution of rat liver fibrosis: hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 1998;102:538-549.
36. Murphy FR, Issa R, Zhou X, Rhatnarajah S, Nagase H, Arthur MJ, et al. Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. J Biol Chem 2002;277:11069-11076.
37. Issa R, Williams E, Trim N, Kendall T, Arthur MJP, Reichen J, et al. Apoptosis of hepatic stellate cells: involvement in resolution of biliary fibrosis and regulation by soluble growth factors. Gut 2001;48:548-557.
38. Parrelli JM, Meisler N, Cutroneo KR. Identification of a glucocorticoid response element in the human transforming growth factor beta 1 gene promoter. Int J Biochem Cell Biol 1998;30:623-627.
39. Centrella M, McCarthy TL, Canalis E. Glucocorticoid regulation of transforming growth factor beta 1 activity and binding in osteoblast-enriched cultures from fetal rat bone. Mol Cell Biol 1991;11:4490-4496.
40. Czaja AJ, Donaldson PT. Gender effects and synergisms with histocompatibility leukocyte antigens in type 1 autoimmune hepatitis. Am J Gastroenterol 2002;97:2051-2057.
41. Czaja AJ. Understanding the pathogenesis of autoimmune hepatitis. Am J Gastroenterol 2001;96:1224-1231.
42. Strettell MDJ, Donaldson PT, Thomson LJ, Santrach PJ, Moore SB, Czaja AJ, et al. Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. Gastroenterology 1997;112:2028-2035.
43. Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on the histological evaluation of chronic hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003;239-244.
44. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. HEPATOLOGY 2003;38:1449-1457.
45. Scheuer PJ. Liver biopsy size matters in chronic hepatitis: bigger is better. HEPATOLOGY 2003;38:1356-1358.
46. Kaserer K, Fiedler R, Steindl P, Muller CH, Wrba F, Ferenci P. Liver biopsy is a useful predictor of response to interferon therapy in chronic hepatitis C. Histopathology 1998;32:454-461.